

ESGCT 30th Annual Congress | BRUSSELS 2023

programme

TIME	ROOM	Gare Maritime	Shed 1	Shed 2A	Shed 2B	Maison de la Poste	BEL	Maritime Room, Maison de la Poste
	08:30 – 09:00		Registration					
09:00 – 11:05						Ballroom	Clinical Trials and Commercialisation Workshop 1	EDUCATION 1B <i>Focus on cell therapy</i> Coffee Break [Foyer]
11:05 – 11:30							EDUCATION 2A <i>Focus on genome engineering [11:15]</i>	Coffee Break [Atrium]
11:30 – 13:00							Clinical Trials and Commercialisation Workshop 2	
12:00 – 14:00		Registration						
14:00 – 16:30				SESSION 1 <i>ESGCT 2023 Opening</i>				
16:30 – 17:00			Coffee Break					
17:00 – 19:00				SESSION 2A <i>Gene transfer and genome editing for cancer immunotherapy</i>	SESSION 2B <i>Lentiviral & integrative vectors</i>	SESSION 2C <i>CNS & sensory diseases I</i>	SESSION 2D <i>Exploring opportunities for scientific-regulatory support</i>	
19:00 – 20:30			Welcome Reception					

TIME	ROOM	Gare Maritime	Shed 1	Shed 2A	Shed 2B	Maison de la Poste	BEL	Maritime Room, Maison de la Poste
	07:30 – 08:30		Registration					
08:30 – 10:30				SESSION 3A <i>Gene editing: Technology development</i>	SESSION 3B <i>AAV, non-integrative vectors I</i>	SESSION 3C <i>Gene therapy for metabolic diseases at preclinical stage</i>	SESSION 3D <i>Innate barriers to nucleic acid delivery</i>	SESSION 3E <i>Regulatory</i>
10:30 – 11:00			Coffee Break					
11:00 – 13:00				SESSION 4 <i>Presidential Symposium</i>				
13:00 – 14:30			Lunch					
13:25 – 14:25					LUNCHTIME SYMPOSIUM: <i>PTC Therapeutics</i>	LUNCHTIME SYMPOSIUM: <i>Dyno Therapeutics</i>	LUNCHTIME SYMPOSIUM: <i>ERC's funding opportunities</i>	LUNCHTIME SYMPOSIUM: <i>GMOs-based ATMPs</i>
14:30 – 16:30				SESSION 5A <i>Infectious diseases & vaccines</i>	SESSION 5B <i>Gene therapy for metabolic diseases at clinical stage</i>	SESSION 5C <i>Oncolytic Immunotherapy & Cancer Gene Therapy</i>	SESSION 5D <i>Accessibility of gene therapy</i>	
16:30 – 19:30		Coffee Break Poster Session 1						
16:30 – 17:30				AGM: ESGCT Annual General Meeting				
17:00 – 18:00								EuroGCT Public Engagement Session
19:30		Molecular Mingle						

ESGCT 30th Annual Congress | BRUSSELS 2023

programme

THURSDAY, 26 OCTOBER 2023	ROOM	Gare Maritime	Shed 1	Shed 2A	Shed 2B	Maison de la Poste	BEL	Maritime Room, Maison de la Poste
	TIME							
	08:30 – 09:00	Registration						
	09:00 – 10:30			SESSION 6A <i>Hematopoietic diseases gene therapy</i>	SESSION 6B <i>Skin & skeletal diseases</i>	SESSION 6C <i>ASGCT</i>	SESSION 6D <i>Bleeding disorders</i>	
	10:30 – 11:00		Coffee Break					
	11:00 – 13:00			SESSION 7 <i>Progress in gene therapies & vaccination: viral vectors, lipid nanoparticles & mRNAs</i>				
	13:00 – 15:00		Lunch					
	13:30 – 14:50				LUNCHTIME SYMPOSIUM: <i>PlasmidFactory</i>	LUNCHTIME SYMPOSIUM: <i>Orchard Therapeutics</i>	LUNCHTIME SYMPOSIUM: <i>The HaDEA</i>	
	15:00 – 17:00			SESSION 8A <i>CART & other engineered T cells</i>	SESSION 8B <i>AAV, non-integrative vectors II</i>	SESSION 8C <i>Non-viral vectors, nanotechnology & RNA therapeutics</i>	SESSION 8D <i>Disease models, IPS cells & organoids</i>	
	17:00 – 17:30		Coffee Break					
	17:30 – 19:30			SESSION 9 <i>Gene editing</i>				
	19:30 – 21:30	Poster Session II						

FRIDAY, 27 OCTOBER 2023	ROOM	Gare Maritime	Shed 1	Shed 2A	Shed 2B	Maison de la Poste	BEL	Maritime Room, Maison de la Poste
	TIME							
	08:00 – 08:30	Registration						
	08:30 – 10:30			SESSION 10A <i>CNS & sensory diseases II</i>	SESSION 10B <i>Gene editing: preclinical development</i>	SESSION 10C <i>PID gene therapy</i>	SESSION 10D <i>Manufacturing</i>	
	10:30 – 11:00		Coffee Break					
	11:00 – 13:00			SESSION 11A <i>Gene editing: towards clinical trials</i>	SESSION 11B <i>CNS & sensory diseases III</i>	SESSION 11C <i>Update on immune response to gene & cell therapy</i>	SESSION 11D <i>Cardiovascular & muscular diseases</i>	
	13:00 – 14:30		Lunch					
	13:25 – 14:25				LUNCHTIME SYMPOSIUM: <i>MaxCyte</i>		LUNCHTIME SYMPOSIUM: <i>EIC Cell & Gene Therapy (CGT) community & EIT-Health CGT companies</i>	
	14:30 – 17:00			SESSION 12 <i>From advanced translational studies to approved therapies</i>				

www.esgctcongress.com

